475 results on '"Xia, Ning-shao"'
Search Results
2. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19
3. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial
4. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
5. Analysis of monoclonal antibodies to establish a universal IVRP method suitable for identifying quadrivalent HPV vaccines that can replace in vivo efficacy tests
6. Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial
7. Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial
8. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
9. Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial
10. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
11. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
12. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma
13. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women
14. Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection
15. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients
16. An optimized high-throughput fluorescence plate reader-based RSV neutralization assay
17. Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study.
18. A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients
19. Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant
20. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans
21. Early diagnosis and population prevention of coronavirus disease 2019
22. Data from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
23. Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
24. Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
25. Supplementary Table 1 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
26. Supplementary Legends from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
27. Ultrafast Microfluidic PCR Thermocycler for Nucleic Acid Amplification
28. Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines
29. Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection
30. Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study
31. Evaluation of a novel chemiluminescent microplate enzyme immunoassay for hepatitis B surface antigen detection
32. Virus-mimetic nanovesicles as a versatile antigen-delivery system
33. Modeling the long-term antibody response of a hepatitis E vaccine
34. Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction
35. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial
36. A novel linear neutralizing epitope of hepatitis E virus
37. Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis
38. An Optimized FI-RSV Vaccine Effectively Protects Cotton Rats and BALB/c Mice without Causing Enhanced Respiratory Disease
39. Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
40. Recent progress in antibody-based therapeutics for triple-negative breast cancer
41. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near‐normal alanine aminotransferase levels
42. Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis.
43. Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors
44. Molecular Evolution of Attachment Glycoprotein (G) and Fusion Protein (F) Genes of Respiratory Syncytial Virus ON1 and BA9 Strains in Xiamen, China
45. Machine Learning for Structure Determination in Single-Particle Cryo-Electron Microscopy: A Systematic Review
46. Additional file 1 of Risk of hepatocellular carcinoma in antiviral treatment-na��ve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
47. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction
48. Estrogen Receptor α Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4α
49. A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway: Erratum
50. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.